Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 9 % of short-term debt in 2025; threshold 65 %.
-
Busy address KBO
12 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
DAXISPHARMA from Anderlecht, company number BE0420720276, closed financial year 2025 with a result of € 166,396 after tax. For that financial year DAXISPHARMA recorded a gross margin of € 7.1 million and equity of € 6 million. Compared with financial year 2024, the result moved from € 204,594 to € 166,396. The company is profitable. The company holds a healthy buffer. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on March 10, 2026.
€ 6 million
▼ 2% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 166,396
▼ 19% vs 2024
Profit after tax over the fiscal year.
€ 149,955
▼ 91% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 300,000 paid out
More than the year’s profit went to the shareholders; reserves fell.
People and assets in 2025
43.9
▼ 0.2 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 6.6 million
▲ 4% vs 2024
€ 149,600 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 90,763
▲ 100% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 16.7 million
▲ 132% vs 2024
Loans from banks and other lenders, long and short.
€ 183,618
▼ 19% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 1.8 million
▲ 27% vs 2024
Taxes, VAT and social contributions still to pay.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 5,505,276 | € 6,005,496 | € 6,852,756 | € 7,066,393 | ▲ 3% |
| Profit after taxes | € 46,885 | € 220,488 | € 204,594 | € 166,396 | ▼ 19% |
| Equity | € 6,294,680 | € 6,515,168 | € 6,119,762 | € 5,986,158 | ▼ 2% |
| Total debts | € 11,039,302 | € 7,671,968 | € 9,652,245 | € 19,239,945 | ▲ 99% |
| Cash | € 6,289,187 | € 265,572 | € 1,652,187 | € 149,955 | ▼ 91% |
| Land & buildings | € 926,937 | € 867,003 | € 806,806 | - | |
| Retained profit | € 684,680 | € 905,168 | € 509,762 | € 376,158 | ▼ 26% |
| Dividend | € 0 | € 0 | € 600,000 | € 300,000 | ▼ 50% |
| Bank debt | € 9,430,391 | € 5,856,837 | € 7,209,172 | € 16,699,864 | ▲ 132% |
| Balance sheet total | € 17,333,982 | € 14,187,136 | € 15,772,007 | € 25,226,104 | ▲ 60% |
| Employees (FTE) | 40 | 41.7 | 44.1 | 43.9 | ▼ 0.2 |
Key figures of DAXISPHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 April 2027.
What happened to DAXISPHARMA?
What happened at DAXISPHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 166,396 (▼ 19% vs 2024). Source: NBB ↗
- Ziad Matta stepped down as director. NBB
- Stéphane Mascarau stepped down as director. NBB
- François Vilette stepped down as director. NBB
- Ziad Matta became a director. NBB
- Stéphane Mascarau became a director. NBB
- François Vilette became a director. NBB
- New establishment in Anderlecht. KBO
In short
From € 46,885 profit in 2022 to € 166,396 profit in 2025.
Paid € 654,781 in corporate taxes since 2022.
Best year ever: 2023, with € 220,488 profit.
On average € 161,000 of value added per employee in 2025.
Management
The shares are held by BIOFARMA (99.6%), Servier Nederland BV (0.2%), Servier Luxembourg SA (0.1%), Servier Benelux SA (0.1%) and Euthérapie Benelux SA (0.1%).
Directors
According to the 2025 annual accounts
Ziad Matta
Managing director
since 2025 · until 2026
Stéphane Mascarau
Director
since 2025 · until 2026
since 2025 · until 2026
Shareholders
BIOFARMA
99.6%
Servier Nederland BV
0.2%
Servier Luxembourg SA
0.1%
0.1%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Bergense Steenweg 1424
1070 Anderlecht
Internationalelaan 57
1070 Anderlecht
Active since 4 October 1980
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 12 companies are registered at this address.
All companies at this address →HILTI BELGIUM
€ 99.8 million revenue · 2024
Servier Benelux same network
€ 89.1 million revenue · 2025
Euthérapie Benelux same network
€ 4.7 million gross margin · 2025
MANUTAN
€ 59.3 million revenue · 2025
COCA-COLA EUROPACIFIC PARTNERS BELGIUM
€ 1.6 billion revenue · 2025
+7 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0420.720.276
- VAT number
- BE 0420.720.276
- Registered office
- Bergense Steenweg 1424, 1070 Anderlecht
- Names & denominations
- DAXISPHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 29 August 1980
- Peppol
- Active · Active since 16 Jan 2026
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Groothandel in farmaceutische producten